| Document |
Document Title |
|
WO/2024/112705A1 |
Provided herein are boronic acid and boronate compounds, compositions, and methods for the treatment of a proliferative disease.
|
|
WO/2024/108774A1 |
It is disclosed a method for synthesizing borylated saturated pyridine and quinoline compounds.
|
|
WO/2024/106666A1 |
The present invention relates to a method for preparing an organoboron compound through hydroboration by using a nickel catalyst. The present invention can effectively perform hydroboration without other external hydrogen cation sources,...
|
|
WO/2024/104206A1 |
Provided in the present invention are an organic electroluminescent material containing a B-N structure, and an electroluminescent device. In the material, on the basis of a traditional B-N resonance structure, an aromatic ring which is ...
|
|
WO/2024/104472A1 |
Provided is a composition, comprising: a pyrene-based organic compound H as a host material, and a light-emitting body E having a narrow emission spectrum, wherein the organic compound H has high stability. The composition may contain an...
|
|
WO/2024/104383A1 |
The present invention relates to an organic compound comprising benzophenanthrene and use thereof in organic photoelectric devices. The organic compound comprising benzophenanthrene has a structure represented by general formula (I). The...
|
|
WO/2024/105066A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2024/107593A1 |
The disclosed and claimed subject matter provides Group 13 (i.e., B, Al, Ga and In) compounds and methods of using the compounds as precursors for deposition of metal-containing films.
|
|
WO/2024/103151A1 |
A compound having a structure of Formula (I), a pharmaceutically-acceptable salt thereof, hydrate thereof, solvate thereof, tautomer thereof, geometric isomer thereof, enantiomer thereof, diastereomer thereof, N-oxide thereof, metabolite...
|
|
WO/2024/101298A1 |
Disclosed are a method for producing pladienolide D that includes a step that reacts a compound represented by formula (A1) with a compound represented by formula (B1) in the presence of a metal catalyst to obtain a compound represented ...
|
|
WO/2024/099517A1 |
The invention relates to salts of 4-hydroxybicyclo[3.3.1]non-3-ene-2,9-dione derivatives. A compound of general formula (IA) or (IB) is provided, where A represents -C=C- and n is 0 or 1; R1 is selected from among the group consisting of...
|
|
WO/2024/100209A1 |
The present invention relates to an organoboron covalent organic network impregnated with at least one salt selected from alkali metal salts and alkaline-earth metal salts, wherein the impregnated organoboron covalent organic network is ...
|
|
WO/2024/102946A2 |
Pharmaceutical compositions and methods for using boron-based ligands of enolases to treat cancer are disclosed. One such pharmaceutical composition includes a therapeutically effective amount of a ligand of enolase (1) having a general ...
|
|
WO/2024/094526A1 |
The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer.
|
|
WO/2024/094827A1 |
The present invention relates to protein ligands against Carbonic Anhydrase IX (CAIX) as target of biomedical relevance. In particular, the highly specific ligands may be able to exclusively interact with antigens expressed on the surfac...
|
|
WO/2024/095863A1 |
The purpose of the present invention is to provide a metal-organic framework (MOF) which readily adsorbs a target substance even when under relatively low pressure. The present invention is a metal-organic framework constituted by specif...
|
|
WO/2024/095862A1 |
The purpose of the present invention is to provide an MOF which has excellent desorption performance. The present invention provides a metal organic framework which is composed of a specific organic ligand and a specific metal ion, where...
|
|
WO/2024/087580A1 |
Disclosed in the present invention are a benzoxazine-functionalized amino-bridged polyaryloxy rare-earth metal complex, and a preparation method therefor and the catalytic use thereof. The preparation method comprises the following steps...
|
|
WO/2024/090836A1 |
The present invention pertains to: a gallium compound; a method for producing same; a thin film deposition composition containing same; and a method for producing a thin film using same. The gallium compound of the present invention has ...
|
|
WO/2024/087156A1 |
A method for synthesizing 4-hydroxy-N,N,2-trimethylbenzimidazole-6-carboxamide. The process comprises: a method of the present invention for synthesizing 4-hydroxy-N,N,2-trimethylbenzimidazole-6-carboxamide. The method has the characteri...
|
|
WO/2024/087419A1 |
Disclosed in the present invention are a nitrogen-containing heterocyclic boronic acid compound, and a preparation method therefor and the use thereof. In the present invention, a three-step reaction is performed using 3-bromo-1-p-toluen...
|
|
WO/2024/088326A1 |
An embodiment of the present application provides an organic compound, comprising a multi-ring structure formed by bonding at least one first structural unit represented by formula (I) and at least one second structural unit represented ...
|
|
WO/2024/090353A1 |
A compound having a structure represented by general formula (1) or (2). The compound has a high luminescent efficiency and excellent durability and has green-light-emitting properties.
|
|
WO/2024/084122A1 |
The present invention relates to the use of BODIPY-derived compounds to detect drugs such as scopolamine, ketamine and cathinones. When the chromophore BODIPY is combined with copper salts, its colour and fluorescence change in the prese...
|
|
WO/2024/081453A1 |
Novel high purity dimethylaluminium chloride compositions are provided that are suitable for semiconductor applications, such as atomic layer etch and aluminum ion implantation. The reduction or minimization of specified gaseous impuriti...
|
|
WO/2024/077407A1 |
Disclosed in the present invention are a chiral reducing agent and a method for synthesizing chiral nicotine. The chiral reducing agent is a compound 1 or a compound 2, or a stereoisomer of the compound 1 and the compound 2. The structur...
|
|
WO/2024/074352A1 |
Provided is a chelate complex comprising (a) a rare earth metal cation M; (b) a chelate ligand of formula (CL1 A) or (CL1 B) c) at least one anionic nucleophilic ligand LN which is coordinated as a further ligand to the rare earth metal ...
|
|
WO/2024/074648A1 |
The present invention relates to a method for precipitating the gadolinium complex of formula (I) from a solution comprising such gadolinium complex by means of mixing a first solution comprising the complex with a second solution, as we...
|
|
WO/2024/075537A1 |
The present invention addresses the problem of providing a reactive compound having excellent storage stability. The present invention relates to a reactive compound represented by formula (1). (In formula (1), Ar1 denotes an aromatic ...
|
|
WO/2024/066619A1 |
The present application provides an organic compound having a general formula of , wherein at least one of ring A, ring A-Y, ring B, ring B-Y, and R has a structure of . The present application also provides a preparation method and use ...
|
|
WO/2024/067923A1 |
The invention relates to a chemical composition, an optoelectronic component (10) comprising at least one chemical composition of this type, and a use of at least one chemical composition of this type in an optolectronic component (10).
|
|
WO/2024/064210A1 |
Disclosed are compounds, compositions, and methods useful for boron neutron capture therapy.
|
|
WO/2024/063095A1 |
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely man...
|
|
WO/2024/062200A1 |
The invention relates to a method for producing a MOF, wherein a MOF is a structured metal-organic compound comprising a two- or three-dimensional porous network consisting of inorganic entities that are connected by polydentate chelatin...
|
|
WO/2024/063529A1 |
The present invention relates to a novel compound and an MRI contrast medium comprising same, the compound having, as a functional group, flavonoids, which are one of natural products having anti-inflammatory, antioxidant and anti-cancer...
|
|
WO/2024/055196A1 |
The present invention relates to an acceptor-donor-acceptor (A-D-A) type organic compound and a preparation method therefor. The material has a thermal activation delayed fluorescence property; a monomolecular structure presents a face-t...
|
|
WO/2024/055195A1 |
The present invention relates to a high-efficiency organic electroluminescent device and a preparation method therefor. A hole injection layer, a hole transport layer, an electron blocking layer, a light-emitting layer, a hole blocking l...
|
|
WO/2024/058103A1 |
The purpose of the present invention is to provide a compound and a colored resin composition which make it possible to produce an optical filter having improved solvent resistance (and preferably, improved solvent resistance, heat resis...
|
|
WO/2024/059650A2 |
Theranostic agents for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells, and use of these agents for detection, staging, and therapy of primary and metastatic prostate can...
|
|
WO/2024/054972A2 |
The present invention provides a compound having the structure: or salt or ester thereof.
|
|
WO/2024/052549A1 |
The present invention relates to a new class of compounds of general formula (I), to the metal chelates with a metal ion suitable for computed tomography thereof, to the Gd3+ chelate complexes thereof, to methods of preparing said compou...
|
|
WO/2024/052250A1 |
The present invention relates to the use of an aminoborane for the preparation of an alkenylaminoborane from a catalyst-free alkyne or in the presence of a catalyst selected from the group of acids consisting of carboxylic acids, sulfoni...
|
|
WO/2024/049087A1 |
Disclosed in the present invention are a novel compound based on pyclen and an MRI contrast agent comprising same. The novel compound and MRI contrast agent of the present invention are characterized by having a structure represented by ...
|
|
WO/2024/048409A1 |
Provided is a composite obtained by bonding, with high strength, a support having a metal part and a metal-organic framework (MOF). The composite comprises a support having a metal part and a metal-organic framework formed on the surfa...
|
|
WO/2023/008865A9 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure represented by formula I wherein Ar1 is selected from the group c...
|
|
WO/2024/047571A1 |
The present invention provides new co-crystal derivatives (coformers: Caffeine, Picolinic Acid, Quinaldic Acid, and Pyridoxine) of 4-((1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile (Crisaborole) having varied dissolut...
|
|
WO/2023/240266A9 |
A composition comprising lithium Li+ and boron cluster weakly-coordinating anions and methods of preparing the same are disclosed. The weakly-coordinating boron cluster anion comprises a formula of [BnXx(OR)y]2- or a salt thereof, wherei...
|
|
WO/2024/042952A1 |
The present invention provides: an acid generator which exhibits excellent solubility in a cationically curable compound; and a curable composition which is rapidly cured when subjected to a heat treatment, and which forms a cured produc...
|
|
WO/2024/044536A2 |
The attachment of glucose to drugs and imaging agents enables cancer cell targeting via interactions with GLUT1 overexpressed on the cell surface. The present technology describes a biomimetic approach for the design of a multivalent glu...
|
|
WO/2024/042951A1 |
Provided is an acid generator that has superior solubility in cation-curable compounds. This acid generator includes: a salt (1) of a cation represented by formula (c-1) and a monovalent counter anion; and a salt (2) of a cation repres...
|
